Daewoong Pharm wins Korea patent for human TPO

Daewoong Pharm said on August 23 that it acquired a patent for human thrombopoeitin (TPO) in Korea, which relates to a process of manufacturing novel TPO derivatives (codename: DWP-40458) containing sialic acid in a high content, following the successful development of novel TOP in 1999.

Chemotherapy regimens may cause cancer patients to develop low levels of platelet in the blood stream tha...